It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
People with Parkinson’s disease (PWP) face critical challenges, including lack of access to neurological care, inadequate measurement and communication of motor symptoms, and suboptimal medication management and compliance. We have developed QDG-Care: a comprehensive connected care platform for Parkinson’s disease (PD) that delivers validated, quantitative metrics of all motor signs in PD in real time, monitors the effects of adjusting therapy and medication adherence and is accessible in the electronic health record. In this article, we describe the design and engineering of all components of QDG-Care, including the development and utility of the QDG Mobility and Tremor Severity Scores. We present the preliminary results and insights from an at-home trial using QDG-Care. QDG technology has enormous potential to improve access to, equity of, and quality of care for PWP, and improve compliance with complex time-critical medication regimens. It will enable rapid “Go-NoGo” decisions for new therapeutics by providing high-resolution data that require fewer participants at lower cost and allow more diverse recruitment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Stanford School of Medicine, Department of Neurology and Neurological Sciences, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
2 Stanford University, Stanford Byers Center for Biodesign, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956)
3 Fastlane Creations, Encinitas, USA (GRID:grid.168010.e)
4 Stanford University, Stanford Byers Center for Biodesign, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956); Stanford School of Medicine, Stanford Medicine Catalyst, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
5 Stanford School of Medicine, Department of Neurology and Neurological Sciences, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford School of Medicine, Department of Neurosurgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)